Table 2.
Clinical data of patients with AVR accompanied by circulating AECA or nota
| Parameter | AECA(+)(n = 13) | AECA(−)(n = 26) | P |
|---|---|---|---|
| Age (yr) | 41.9 ± 7.6 | 38.5 ± 6.6 | 0.161 |
| Gender (male/female) | 8/5 | 15/11 | 1.000 |
| Previous renal transplantation (%) | 2 (15.4) | 0 (0.0) | 0.105 |
| Pretransplantation CDC positive (%) | 0 | 0 | – |
| PRA positive (n [%]) | |||
| before transplantation | 2 (15.4) | 4 (15.4) | 1.000 |
| on rejection | 2/12 (16.7) | 7 (26.9) | 0.689 |
| Baseline immunosuppressants (n [%]) | |||
| MMF+CsA+Pred | 5 (38.5) | 10 (38.5) | 1.000 |
| MMF+TAC+Pred | 6 (46.2) | 14 (53.8) | 0.741 |
| Aza+CsA+Pred | 2 (15.4) | 2 (7.7) | 0.589 |
| IL-2mAb induction | 5 (38.5) | 10 (28.5) | 1.000 |
a
AVR, acute vascular rejection; Aza, azathioprine; CDC, complement-dependent cytotoxicity cross-match; CsA, cyclosporine; MMF, mycophenolate mofetil; Pred, prednisone; TAC, tacrolimus.